ENTITY
WuXi AppTec

WuXi AppTec (2359 HK)

622
Analysis
Health Care • China
WuXi AppTec is a global contract research, development, and manufacturing organization (CRDMO) for the pharmaceutical and life sciences industries. It provides integrated, end-to-end services including chemistry drug CRDMO, biology discovery, preclinical testing, and clinical research services for various therapeutic modalities. The company was founded in 2000 and is headquartered in Shanghai, China.
more
•11 Oct 2026 10:10

HK Short Interest Weekly: Lenovo, Baba, Meituan, Tencent, Kb Laminates, Zj Innolight

We analyzed the latest HK SFC report for aggregate short position as of Oct 2nd and highlight short interest changes in Lenovo, Baba, Meituan,...

Logo
89 Views
Share
•13 Aug 2026 09:50

HONG KONG ALPHA PORTFOLIO: (July 2026)

We made several adjustments to the portfolio yesterday. We sold the Baidu (9888) position since it hit our stop-loss level. We also sold the...

Logo
164 Views
Share
•12 Aug 2026 13:10

CHINA/HK: AI & RX - Together At Last !!

China's AI-driven drug discovery (AIDD) sector is growing rapidly, with leading drug and biotech companies entering R&D and drug-development...

Logo
112 Views
Share
•08 Aug 2026 16:21

China Healthcare Weekly Wrap (3-7 Aug)

Wuxi Apptec 2Q results beat; BeOne 2Q driven by robust Brukinsa; Innovent robust 2Q product revenue +13% QoQ; Alphamab licensed-out TROP2/HER3 ADC...

Logo
117 Views
Share
bullish•WuXi AppTec
•02 Nov 2025 10:04

China Healthcare Weekly (Nov.2) - 11th National VBP, More BD Deal to Come, WuXi AppTec 25Q3 Results

"Anchor price" mechanism in 11th VBP leads to increased rationality.MNCs' interest in China assets not yet saturated, more deals expected.WuXi...

Logo
526 Views
Share
x